Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 3/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31200322 | 0.81 | CYP2A6 (0.41) | CYP11B2CYP2A6PTK2CYP11B1ALDH1A1 | |
| SCHEMBL28240638 | 0.77 | MEN1 (0.41) | ALDH1A1MAPTL3MBTL1ADORA1KDM4E | |
| SCHEMBL3971543 | 0.75 | POLB (0.44) | ALDH1A1MAPTL3MBTL1KDM4EPOLB | |
| SCHEMBL30991226 | 0.72 | CYP2A6 (0.39) | CYP11B2CYP2A6PTK2CYP11B1PGR | |
| SCHEMBL3972438 | 0.72 | MMP2 (0.44) | CYP2A6MAPTPTGS2 | |
| SCHEMBL3972288 | 0.72 | PTGS2 (0.38) | L3MBTL1ADORA1KDM4EPTGS2POLB | |
| SCHEMBL3974458 | 0.72 | RAB9A (0.40) | CYP11B2CYP2A6ALDH1A1KDM4EPOLB | |
| SCHEMBL2685157 | 0.72 | AURKB (0.41) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL7371813 | 0.69 | CYP1A2 (0.47) | ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL14392676 | 0.69 | CYP2A6 (0.61) | CYP11B2CYP2A6PTK2CYP11B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118336-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-2016068-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | AstraZeneca AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007129052-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118336-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MTOR, RICTOR, PIK3R5 | CYP11B2 265/4885CYP2A6 1100/4885PTK2 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.